The effects of calcitriol and nicotinamide on residual pancreatic β-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI)

Diabetic Medicine

Volumn 23, Issue 8, 2006, Pages 920-923

  Pitocco, D ^a   Crino A ^b   Di Stasio, E ^a   Manfrini, S ^c   Guglielmi, C ^c   Spera, S ^c   Beretta Anguissola, G ^c   Visalli, N ^d   Suraci, C ^d   Matteoli, M C ^b   Patera, I P ^b   Cavallo, M G ^e   Bizzarri, C ^b   Pozzilli, P ^c,f  

^a CATHOLIC UNIVERSITY   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d SANDRO PERTINI HOSPITAL   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Calcitriol; Nicotinamide; Type 1 diabetes

Indexed keywords

C PEPTIDE; CALCITRIOL; HEMOGLOBIN A1C; INSULIN; NICOTINAMIDE; VITAMIN D;

ADOLESCENT; ARTICLE; CELL FUNCTION; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DOSE RESPONSE; DRUG EFFECT; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; VITAMIN SUPPLEMENTATION;

ADOLESCENT; BLOOD GLUCOSE; CALCITRIOL; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; NIACINAMIDE; PILOT PROJECTS;

EID: 33746580370     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.01921.x     Document Type: Article

References (16)

1. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive therapy on residual β-cell function in patients with Type 1 diabetes in the Diabetes Control and Complication Trial. Ann Intern Med 1998; 128: 517-523.
2. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H et al. C-peptide is the appropriate outcome measure for Type 1 diabetes clinical trials to preserve β-cell function; report of an American Diabetes Association (ADA) workshop, 21-22 October 2001. Diabetes 2004; 53: 250-264.
3. Deluca HF, Cantorna MT. Vitamin D; its role and uses in immunology. FASEB J 2001; 14: 2579-2585.
4. Cantorna MT, Hayes CE, Deluca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis. Proc Natl Acad Sci USA 1996; 93: 7861-7864.
5. Cantorna MT, Munsick C, Bemiss C, Mhon B. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000; 11: 2648-2652.
6. Mathieu C, Gysemans C, Giulietti A, Bouillon R. Vitamin D and diabetes. Diabetologia 2005; 48: 1247-1257.
7. The EURODIAB Substudy Group. Vitamin D supplement in early childhood and risk for Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1999; 42: 51-54.
8. Hypponen E, Läärä E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of Type 1 diabetes; a birth-cohort study. Lancet 2001; 358: 1500-1503.
9. Pozzilli P, Browne PD, Kolb H. Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists. Diabetes Care 1996; 19: 1357-1363.
10. Gale EA, Bingley PJ, Emmett CL, Collier T, European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomized controlled trial of intervention before the onset of Type 1 diabetes. Lancet 2004; 363: 925-931.
11. Hawa M, Rowe R, Lan MS, Notkins Al Pozzilli P, Christie MR et al. Value of antibodies to islet protein tyrosine phosphatase-like molecule in predicting type 1 diabetes. Diabetes 1997; 46: 1270-1275.
12. Pozzilli P, Pitocco D, Visalli N, Cavallo MG, Buzzetti R, Crino A et al. No effect of oral insulin on residual β-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 2000; 43: 1000-1004.
13. 3 and 1,25-dihydroxy vitamin D3 in patients with recent onset type 1 diabetes. Horm Metab Res 2005; 37: 680-683.
14. 1c levels at diagnosis indicate a different pethogenetic process depending on the age at onset of type 1 diabetes. Diabetologia 2004; 47: A185.
15. Inukai T, Matsutomo R, Tayama K, Aso Y, Takemura Y. Relation between the serum level of C-peptide and risk factors for coronary heart disease and diabetic microangiopathy in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 1999; 107: 40-45.
16. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26: 832-836.